Evidence map›Paper›PMID 39735247›Full record

ReviewJournal of market access & health policy2024

Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies.

Christos Ntais, Michael A Talias, John Fanourgiakis, Nikolaos Kontodimopoulos

Abstract readReview
In one paragraph

Review in Journal of market access & health policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christos NtaisHealthcare Management Program, School of Economics & Management, Open University of Cyprus, Nicosia 2220, Cyprus; christos.ntais@st.ouc.ac.cy.ORCID https://orcid.org/0000-0002-2749-101X
Michael A TaliasHealthcare Management Program, School of Economics & Management, Open University of Cyprus, Nicosia 2220, Cyprus; christos.ntais@st.ouc.ac.cy.ORCID https://orcid.org/0000-0002-1802-5586
John FanourgiakisDepartment of Management Science and Technology, Hellenic Mediterranean University, 72100 Agios Nikolaos, Greece; jfanourgiakis@hmu.gr.ORCID https://orcid.org/0000-0001-5364-7412
Nikolaos KontodimopoulosDepartment of Economics and Sustainable Development, Harokopio University, 17676 Athens, Greece; nkontodi@hua.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis paper reviews cost containment policies to control pharmaceutical expenditure either by regulating the pharmaceutical industry or targeting the demand side.

methodsThe method used was the narrative literature review of studies which assessed the effect of pharmaceutical cost containment policies.

resultsGovernments worldwide have implemented a great variety of policy measures to manage pharmaceutical expenditure while ensuring fair access to essential medicines. Cost-sharing schemes, value-based pricing, reimbursement, reference pricing, payback mechanisms and the substitution of original drugs with generics and biosimilars are pivotal in these efforts, albeit with differing effectiveness across healthcare systems. Overall, it appears that any gains may be outweighed by the unfavorable effects of policies impacting patients. Although interventions have been created to improve physicians' prescribing practice, they often achieve very minor benefits and at considerable cost. Policy measures pertaining to the regulation of the supply side must be supported by thorough evaluation in order to ascertain costs and effects and guarantee that unintended consequences are minimized.

conclusionsPolicymakers frequently enact numerous laws and regulations to control pharmaceutical expenditure, even if there is limited evidence that they are cost-effective. The most crucial component of any policy's success, regardless of the one selected, is its evaluation. Further research is needed to develop context-specific guidance that balances cost containment, equity and sustainability.

Indexed as

clawbackcost containment policiescost-sharing schemesdrug price regulationhealth technology assessmentpharmaceutical expenditure

Identifiers

PMID39735247
PMCPMC11677551

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.